ea0049ep606 | Diabetes therapy | ECE2017
, Masood Qamar
Background: Rabson Mendenhall Syndrome (RMS) is a rare genetic syndrome that is caused by the mutation in the insulin receptor gene. Such mutation consequently results in severe insulin resistance. Patients suffering from RMS develop constant hyperglycemia from a progressive decline of endogenous insulin secretion. Drug therapy for RMS includes metformin, pioglitazones, large doses of insulin alongwith recombinant human methionyl leptin or IGF-1. Here we describe a case of RMS...